Tech Company Financing Transactions
Nuclea Biotechnologies Funding Round
Nuclea Biotechnologies, based in Cambridge, raised $5 million from private investors.
Transaction Overview
Company Name
Announced On
8/2/2012
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series C
Investors
Proceeds Purpose
The company will use the proceeds to support clinical trials and new hires related to the development of its fatty acid synthase tests for prostate and breast cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Acorn Park Dr. 6th Floor
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Nuclea Biotechnologies' primary mission is to conduct genomic research in the oncology field so as to discover biomarkers and gene or protein expression profiles that are unique to oncologic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Deborah August
Chief Operating Officer
Mary Lopez
VP - Bus. Development
Bryan Krastins
VP - General Counsel
Paula Evans
VP - Regulatory Affairs
Sheryl Brown-Shimer
Browse more venture capital transactions:
Prev: 8/2/2012: Plink venture capital transaction
Next: 8/2/2012: iConnectivity venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs